Scinai Immunotherapeutics Ltd ADR Dossier - Source-backed chat

Scinai Immunotherapeutics Ltd ADR

SCNINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.72

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.31Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $887.6K

Shares Outstanding 677.6K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Scinai Immunotherapeutics is executing a strategic transition toward a dual-model business, combining its early-stage immunology R&D pipeline with a revenue-generating CDMO platform (Scinai Biopharma Services). The recent acquisition of Recipharm Israel's Yavne facility significantly expands its capabilities into small-molecule development and sterile injectables, positioning the company to target $5 million in CDMO revenues for 2026. However, the company continues to face severe financial constraints, including a substantial accumulated deficit and high cash burn relative to its cash reserves, making its near-term survival highly dependent on successful CDMO execution and non-dilutive grant funding.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1020%

The company fails to integrate the Yavne facility efficiently, resulting in operational bottlenecks and missed revenue targets. Inability to secure non-dilutive grants forces highly dilutive equity financings or reverse stock splits to maintain Nasdaq compliance, while the cash runway is exhausted, raising substantial doubt about its ability to continue as a going concern.

Base CaseCentral scenario

$0.5055%

Scinai slowly scales its CDMO operations, achieving moderate revenue growth that falls slightly short of the ambitious $5 million target but demonstrates clear commercial traction. The company relies on a mix of small-scale private placements (such as the $2.61 million financing in April 2026) and partial grant funding to sustain its lean R&D structure, while managing ongoing Nasdaq listing compliance challenges.

Bull CaseUpside scenario

$1.5025%

The integration of the Yavne facility and the strategic collaboration with Recipharm AB successfully drive CDMO revenues to the $5 million target in 2026 and achieve unit breakeven by the end of 2026. Concurrently, the company secures non-dilutive FENG grants to advance its flagship PC111 program and IL-17 NanoAb programs through clinical proof-of-concept without diluting shareholders.

Scenarios reflect our research view at the research date.

Key Investment Merits

Dual business model provides near-term CDMO revenue to offset high-risk, early-stage R&D investments.
Acquisition of Recipharm Israel (Yavne site) expands capabilities into small molecules and sterile injectables, backed by a strategic commercial collaboration with Recipharm AB.
Differentiated lifecycle CDMO model with global reach, allowing customer programs to transition from early-stage to commercial manufacturing.
Flagship PC111 program targets severe dermatological conditions with high unmet needs and orphan drug potential.

Key Investment Risks

Severe financial stress with a history of operating losses and substantial doubt regarding its ability to continue as a going concern.
High execution risk in integrating the newly acquired Yavne facility and scaling CDMO revenues from $1.3 million in 2025 to the $5 million target in 2026.
Risk of delisting from Nasdaq if the company fails to maintain the minimum bid price of $1.00 per share.
R&D pipeline is highly preclinical, with clinical trials for the lead anti-IL-17 NanoAb not planned until 2027.

Thesis Invalidation Triggers

Failure to secure the FENG grant funding for PC111 or IL-17 programs.
Inability to meet the $5 million CDMO revenue target for fiscal year 2026.
Delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.
Termination or non-renewal of the PinCell option agreement for PC111 beyond August 31, 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.